Comparative Efficacy of Disease-Modifying Treatments for Relapsing Multiple Sclerosis —Variations in Real-World Experience

With great interest we read the study by Roos et al comparing the efficacy of 2 anti-CD20 disease-modifying therapies (DMTs) commonly used for relapsing multiple sclerosis (MS). As no head-to-head randomized clinical trials (RCTs) have been completed, the comparative effectiveness of ocrelizumab and rituximab on relapse reduction was evaluated in patients from the MSBase and Danish MS registries. Over a mean follow-up of 1.4 years, the annualized relapse rate (ARR) for patients treated with rituximab was 0.20, whereas for ocrelizumab it was 0.09. Noninferiority was not demonstrated for treatment with rituximab when compared with ocrelizumab.
Source: JAMA Neurology - Category: Neurology Source Type: research